To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)

NCT04606329 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Diseases

Interventions

DRUG: LuminoMark inj.(Conc. for fluorescence)
DRUG: Charcotrace Inj.

Sponsor

Hanlim Pharm. Co., Ltd.